Current Research in Triple-Negative Breast Cancer

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).

Clinical Pearls:

• TNBC is an area of unmet need and is defined by the absence of a druggable target
• Researchers have studied Src inhibition and PARP inhibition in this space
• A new PARP inhibitor, BMN 673, looks particularly potent forBRCA-mutated breast cancer
• Patients withBRCA-mutated breast cancer are often triple negative
• There is still a need to better understand the biology of TNBC in order to bring the right drugs to these patients